

Summit Therapeutics PLC

13:05 09 Jul 2019

Latest data shows potential of Summit Therapeutics' DDS-04 antibiotic to treat pneumonia and sepsis

Summit Therapeutics PLC (LON:SUMM) has shown that its next generation of antibiotics have the potential to treat potentially deadly infections such as pneumonia and sepsis.

AIM-quoted Summit, which is also listed on the Nasdaq in New York, tested compounds from its DDS-04 series on mice which had been infected with the two conditions.

READ: Summit in line to receive up to US\$64mln in funding from US government

The DDS-04 compound cured the mice with sepsis, while it 'significantly reduced' the bacterial burden in the lungs in those with pneumonia.

The data build on previous preclinical research in urinary tract infections and suggest that DDS-04 has potential to treat Enterobacteriaceae infections in all three key infection sites: urinary tract, bloodstream and lung.

It is the latter two where there is the greatest unmet patient need, Summit said.

No new antibiotics this century

"There is a great need to advance truly differentiated treatments for Gram-negative bacteria, where there have been no new classes of antibiotics discovered since the last century," said Summit's president of R&D, David Roblin.

"In particular, the rise of untreatable and hard to treat Enterobacteriaceae infections is a frightening prospect.

"DDS-04 aligns with our strategy of targeting pathogenic bacteria and seeking to preserve patients' good bacteria known to play an important role in overall patient health."

In early afternoon trading, Summit shares gained 3.2% at 24.50p.

-- Updates share price --

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security,

Price: 21.221

Market Cap: £34.06 m

1 Year Share Price Graph



December 2018 June 2019 December 20

Share Information

Code: SUMM

Listing: AIM

52 week High Low
34.666 9.5

Sector: Pharma & Biotech

Website: www.summitplc.com

Company Synopsis:

Summit Therapeutics is a leader in antibiotic innovation. Summit's new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. The company is currently developing new mechanism antibiotics for infections caused by *C. difficile*, *N.*

action@proactiveinvestors.com

portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to
Twenty Five Thousand dollars (\$25,000).